Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases, with an initial emphasis on oncology [1][4] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate potential drug targets within the chromatin regulatory system, which has the potential to transform treatment options for a wide range of diseases [1][4] Conference Participation - Foghorn management will participate in the Jefferies London Healthcare Conference on November 19, 2024, with a fireside chat led by CEO Adrian Gottschalk [2] - The company will also engage in one-on-one meetings during the 7th Annual Evercore HealthCONx Conference on December 3, 2024, and the Citi Global Healthcare Conference on December 4, 2024 [3][2] Company Overview - Foghorn Therapeutics is dedicated to discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, with multiple product candidates currently in development for oncology [4]